Lapatinib, a dual reversible EGFR/HER2 small-molecule tyrosine kinase inhibitor, is currently being assessed in the maintenance setting versus placebo (both in combination with chemoradiotherapy) in a phase III study in patients with high-risk HNSCC who have undergone resection [32]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.